Market cap
$185 Mln
Recently Viewed
Clear AllMarket cap
$185 Mln
Revenue (TTM)
$10 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-79 Mln
ROE
-0.5 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-15.7
Debt to Equity
0
Book Value
$3.2
EPS
$-2.1
Face value
--
Shares outstanding
58,236,900
CFO
$-239.58 Mln
EBITDA
$-312.99 Mln
Net Profit
$-294.59 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Graphite Bio Inc (GRPH)
| 21.4 | 6.0 | 35.3 | 36.5 | -- | -- | -- |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Graphite Bio Inc (GRPH)
| -21.1 | -73.3 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Graphite Bio Inc (GRPH)
|
22.3 | 185.2 | 0.0 | -124.7 | -494.4 | -52 | -- | 1.0 |
| 0.9 | 3.0 | 1.2 | -113.0 | -7,739.1 | -90 | -- | 0.0 |
As of March 21, 2024, Graphite Bio, Inc. was acquired by LENZ Therapeutics, Inc., in a reverse merger transaction. Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in... the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California. Read more
President, CEO, COO, Principal Executive, Financial & Accounting Officer and Director
Ms. Kimberlee Cobleigh Drapkin CPA
President, CEO, COO, Principal Executive, Financial & Accounting Officer and Director
Ms. Kimberlee Cobleigh Drapkin CPA
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Graphite Bio Inc (GRPH) is $22.26 (NASDAQ) as of 22-Mar-2024 09:30 EDT. Graphite Bio Inc (GRPH) has given a return of 36.48% in the last 1 years.
Since, TTM earnings of Graphite Bio Inc (GRPH) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-1.22
|
0.83
|
|
2022
|
-1.92
|
0.62
|
|
2021
|
-11.12
|
1.73
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of Graphite Bio Inc (GRPH) are Rs -- and Rs -- as of 26-Apr-2026.
Graphite Bio Inc (GRPH) has a market capitalisation of $ 185 Mln as on 01-Apr-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Graphite Bio Inc (GRPH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.